Recombinant Human Adenosine receptor A1 (ADORA1)

What expression systems are commonly used for recombinant ADORA1 production?

Multiple expression systems can be used to produce recombinant ADORA1, each with different advantages:

Based on available commercial options, researchers frequently use cell-free expression systems for full-length ADORA1, achieving ≥85% purity suitable for SDS-PAGE analysis . Mammalian expression systems are preferred when studying receptor signaling pathways to ensure proper coupling to G proteins .

How can I verify the functionality of recombinant ADORA1?

Functional verification of recombinant ADORA1 typically involves:

• Ligand binding assays: Using radioliganded binding assays with selective A1 receptor agonists like [³H]2-chloro-N6-cyclopentyladenosine (CCPA) or antagonists like [³H]8-cyclopentyl-1,3-dipropylxanthine (DPCPX) . These assays confirm proper protein folding and ligand binding pocket formation.

• G protein coupling assays: Measuring inhibition of adenylyl cyclase activity, as ADORA1 activation leads to decreased cAMP levels through Gi/Go protein coupling .

• Potassium channel modulation: Functional ADORA1 activates several types of potassium channels while inhibiting N-, P-, and Q-type calcium channels .

• Cellular signaling studies: Measuring downstream effects such as MAPK pathway activation in CHO cells or PKC activation via βγ subunits of Gi/o proteins .

Positive controls using native tissue preparations (e.g., brain membrane fractions) are recommended for comparison, as recombinant and native receptors should display similar pharmacological profiles .

What are the critical domains of ADORA1 involved in ligand binding and selectivity?

Research using chimeric receptors has identified key structural regions of ADORA1 involved in ligand binding:

The most critical determinants for both agonist and antagonist binding and ligand specificity are present in transmembrane domains (TMs) 1-4 . Specifically:

• Replacing TM1 of A2aAR with the corresponding A1AR region enables some CCPA binding, but with low affinity

• Adding A1AR TMs 2-4 markedly improves binding affinity

• TMs 1-4 of A1AR confer wild-type receptor affinity for antagonists like DPCPX

• When comparing binding properties of constructs containing A1AR TMs 1-4, TMs 1-6, and wild-type A1AR, no significant differences were found across 10 different compounds

Notably, truncated A1AR constructs extending from the amino terminus to just after TM4 showed no binding, indicating that the amino half of the receptor alone is insufficient for ligand binding. This suggests ligand binding requires proper folding and assembly of the complete receptor structure .

The second extracellular loop has also been implicated in ligand binding characteristics, with studies comparing human and mouse ADORA1 finding that four amino acid differences in this region may account for their markedly different ligand binding properties despite 90% sequence identity .

How do different cellular environments affect ADORA1 expression and function?

The cellular environment can significantly impact ADORA1 function and regulation:

What mechanisms regulate ADORA1 desensitization and internalization in recombinant systems?

ADORA1 undergoes complex regulatory processes that can be studied in recombinant systems:

• Desensitization kinetics: Unlike other adenosine receptors, A1AR is phosphorylated and internalized slowly, with a half-life of several hours, compared to A2A/B receptors (about one hour) and A3 receptors (minutes) .

• G protein coupling changes: In both recombinant systems and native tissues, chronic A1AR agonist exposure leads to decreased receptor levels and reduced inhibition of adenylyl cyclase, accompanied by decreased levels of pertussis-sensitive G proteins and increased levels of Gs proteins .

• Phosphorylation mechanisms: Rapid translocation of G protein-coupled receptor kinase (GRK) from cytosol to plasma membrane and subsequent A1AR phosphorylation has been demonstrated within one hour of agonist treatment. Phosphorylated A1AR displays enhanced affinity for arrestin over Gi/Go G-proteins .

• β-arrestin/ERK1/2 pathway: Long-term (24h) agonist exposure decreases A1AR membrane protein but increases A1AR mRNA 11-fold. This effect depends on β-arrestin1, as its knockdown blocks agonist-mediated down-regulation and suppresses ERK1/2 and AP-1 activities .

• Recovery mechanisms: After agonist withdrawal, rapid recovery of plasma membrane A1AR occurs, dependent on de novo protein synthesis and ERK1/2 activity but independent of β-arrestin1 and NF-κB .

These findings provide methodological approaches for studying receptor regulation in recombinant systems, which can be verified by comparison with native receptor behavior.

How can I design experiments to study ADORA1-mediated angiogenesis?

ADORA1 activation has been shown to promote angiogenesis through specific mechanisms:

Experimental design should include:

• Appropriate controls (vehicle, selective antagonists)

• Concentration-response curves for agonists

• Verification using both pharmacological tools and genetic approaches

• Comparison of direct versus indirect effects

• Analysis of downstream mediators (particularly VEGF)

This approach allows researchers to distinguish between direct effects on endothelial cells and indirect effects mediated through inflammatory cells.

What methods are available for studying ADORA1 expression in specific cell populations?

Several approaches can be used to study cell-specific expression of ADORA1:

• In situ hybridization (ISH): This technique has been used to profile the expression of Adora1 transcripts in subclasses of neurons (glutamatergic, GABAergic) and glia (astrocytes, oligodendrocytes, microglia) in the auditory forebrain of adult mice. Results indicate that Adora1 is widely expressed but in a manner that varies by cell type and specific location .

• Single-cell RNA sequencing: This approach can identify cell-specific expression patterns and has important implications for the design of experimental studies targeting Adora1 (e.g., optogenetics, gene editing, pharmacology, behavior) .

• Immunohistochemistry with validated antibodies: Several commercial antibodies are available for ADORA1 detection in various applications including Western blotting (1:500-1:2000 dilution), immunohistochemistry (1:50-1:200), immunofluorescence (1:50-1:200), immunoprecipitation (1:50), and flow cytometry (1:100) .

• Receptor autoradiography: Using selective radioligands to map receptor distribution in tissue sections.

Understanding cell-specific expression is crucial because A1R-mediated adenosine signaling differentially impacts subpopulations of neurons and glia in various brain regions .

What are the common challenges in producing functional recombinant ADORA1 and how can they be overcome?

Researchers face several challenges when producing recombinant ADORA1:

• Protein instability: As a GPCR, ADORA1 contains hydrophobic transmembrane domains that can cause aggregation and misfolding.

  • Solution: Include stabilizing agents like glycerol (50%) in storage buffers and use detergents optimized for membrane proteins .

• Low expression levels: GPCRs often express poorly in heterologous systems.

  • Solution: Optimize codon usage for the expression host, use strong inducible promoters, and consider fusion partners that enhance expression.

• Post-translational modifications: Different expression systems produce varying glycosylation patterns.

  • Solution: Select the expression system based on research needs; mammalian cells for native-like modifications, E. coli for studies where glycosylation isn't critical.

• Verification of functionality: Confirming proper folding and activity.

  • Solution: Use multiple complementary assays including ligand binding, G-protein coupling, and downstream signaling responses .

• Storage stability: Recombinant GPCRs can lose activity during storage.

  • Solution: Store at -20°C for up to one year, avoid repeated freeze-thaw cycles, and use stabilizing buffer conditions (pH 7.4, 150mM NaCl, 0.02% sodium azide, 50% glycerol) .

How do species differences affect ADORA1 function and experimental design?

Species differences in ADORA1 can significantly impact experimental results:

• Sequence homology: Human and mouse ADORA1 sequences are 90% identical, yet their ligand binding properties differ markedly when expressed in the same cell line . This is particularly relevant when using animal models to study compounds intended for human applications.

• Extracellular loops: Four amino acid differences occur in the second extracellular loop between human and mouse receptors, which may account for binding differences .

• Experimental design considerations:

  • Use species-appropriate ligands and concentration ranges

  • Include proper controls from the species being studied

  • Be cautious when extrapolating results across species

  • Consider creating humanized animal models for translational research

  • When comparing pharmacological profiles, test compounds against receptors from multiple species

• Verification approaches: When studying novel compounds, test against recombinant receptors from both the experimental animal model and human ADORA1 to establish species-specific pharmacology profiles .

What techniques can be used to study ADORA1 interaction with other signaling molecules?

Investigating ADORA1 interactions with other signaling molecules requires specialized techniques:

• Co-immunoprecipitation: Using selective antibodies for ADORA1 (available as recombinant monoclonal antibodies with various conjugations including biotin, HRP, and FITC) to pull down receptor complexes and identify interacting partners.

• BRET/FRET assays: Bioluminescence/Fluorescence Resonance Energy Transfer techniques can detect protein-protein interactions in living cells, useful for studying:

  • Receptor homo- and heterodimerization with other GPCRs

  • Interactions with G proteins and arrestins

  • Recruitment of signaling molecules

• Proximity ligation assays: Detecting interactions between ADORA1 and other proteins within cells at endogenous expression levels.

• Crosslinking studies: Chemical crosslinking followed by mass spectrometry to identify interaction interfaces.

• Functional complementation: Split reporter systems to verify protein-protein interactions.

Studies have shown that ADORA1 activation leads to:

• Binding of Gi1/2/3 or Go proteins

• Inhibition of adenylate cyclase

• Activation of phospholipase C

• Increased inositol triphosphate/diglyceride concentration

• Activation of potassium channels

• Inhibition of N-, P-, and Q-type calcium channels

Each of these interactions can be studied using specific assays designed to measure the relevant functional outcomes.

How is ADORA1 involved in cell-specific responses to hypoxia and oxidative stress?

ADORA1 plays important roles in cellular responses to hypoxia and oxidative stress:

• Hypoxia-induced regulation: Studies in rat hippocampal slices showed that hypoxia decreases the density of A1AR. This desensitization can be mimicked by 2-chloroadenosine (CADO) and prevented by the A1AR antagonist DPCPX, suggesting that hypoxia leads to increased extracellular adenosine levels and subsequent rapid (<90 min) desensitization of A1AR .

• Cell-specific responses: In C6 glioma cells subjected to hypoxia (2, 6, and 24h), there is down-regulation of A1AR and up-regulation of A2AAR. This effect depends on adenosine release, as adenosine deaminase blocks it. Interestingly, increased A2AAR expression induced by hypoxia is inhibited by A1AR antagonist DPCPX but not by A2AAR antagonist ZM 241385, indicating cross-regulation between receptor subtypes .

• Protective mechanisms: Decreased A1AR expression appears to prevent hypoxia-induced ventricular dilatation and white matter loss, suggesting that pharmacological blockade of A1AR may have clinical utility in certain hypoxic conditions .

• Oxidative stress sensing: Some adenosine receptors serve as sensors of cellular oxidative stress, with signals transmitted by transcription factors such as nuclear factor (NF)-κB to regulate receptor expression .

These findings provide several experimental approaches to study ADORA1 involvement in stress responses across different cell types.

What is the current understanding of ADORA1 oligomerization and how can it be studied?

ADORA1 can form both homo-oligomers and hetero-oligomers with other receptors:

• Homodimerization: A1AR can form homodimers that may have distinct signaling properties compared to monomeric receptors .

• Heteromerization partners: A1AR can form functional heteromers with:

  • Other adenosine receptors (particularly A2AAR)

  • Dopamine receptors

  • Other GPCRs

• Functional consequences: Heteromerization can affect:

  • Ligand binding properties

  • G-protein coupling selectivity

  • Signal transduction pathways

  • Receptor trafficking and internalization

• Experimental approaches:

  • Resonance energy transfer techniques (BRET/FRET)

  • Proximity ligation assays in native tissues

  • Co-immunoprecipitation with subtype-specific antibodies

  • Functional complementation assays

  • Bimolecular fluorescence complementation

• Validation methods: Combinations of mutations, chimeric constructs, and interfering peptides that disrupt specific interfaces can help validate protein-protein interaction sites .

Understanding oligomerization is important because it may explain why certain pharmacological effects cannot be attributed to individual receptor subtypes and may provide opportunities for developing more selective therapeutic approaches.

How can ADORA1 research contribute to understanding central nervous system disorders?

ADORA1 research has significant implications for understanding CNS disorders:

• Neuronal expression patterns: ADORA1 is widely distributed on neurons in the cortex, hippocampus, and cerebellum, where it modulates the release of neurotransmitters including glutamate, acetylcholine, serotonin, and GABA .

• Glial expression: ADORA1 is also present on astrocytes, oligodendrocytes, and microglia, suggesting roles beyond neuronal signaling . In situ hybridization studies have mapped the expression of Adora1 transcripts in various cell types across laminae in primary auditory cortex .

• Sleep regulation: A1 receptors participate in sleep promotion by inhibiting arousal of cholinergic neurons in the basal forebrain .

• Neuroprotection: ADORA1 activation can protect against excitotoxicity, which is relevant to stroke, epilepsy, and neurodegenerative diseases.

• Experimental approaches:

  • Cell-specific genetic manipulation (conditional knockouts)

  • Optogenetic approaches targeting ADORA1-expressing neurons

  • Pharmacological studies with selective agonists/antagonists

  • Single-cell transcriptomics to identify disease-specific changes in expression

Understanding cell-specific expression patterns has important implications for experimental design when targeting ADORA1 using techniques like optogenetics, gene editing, or pharmacology, as target specificity significantly impacts experimental outcomes .